Molecular profile in body fluids in subjects enrolled in a randomised trial for lung cancer screening: Perspectives of integrated strategies for early diagnosis

2006, Italian cancer figures—report 2006: 1. Incidence, mortality and estimates, Epidemiol Prev, 30 Peto, 2000, Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies, BMJ, 321, 323, 10.1136/bmj.321.7257.323 Marcus, 2006, Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis, J Natl Cancer Inst, 98, 748, 10.1093/jnci/djj207 Henschke, 1999, Early Lung Cancer Action Project: overall design and findings from baseline screening, Lancet, 354, 99, 10.1016/S0140-6736(99)06093-6 Mulshine, 2008, Commentary: lung cancer screening—progress or peril, Oncologist, 13, 435, 10.1634/theoncologist.2008-0068 Henschke, 2006, Survival of patients with stage I lung cancer detected on CT screening, N Engl J Med, 355, 1763, 10.1056/NEJMoa060476 Zochbauer-Muller, 2002, Molecular pathogenesis of lung cancer, Annu Rev Physiol, 64, 681, 10.1146/annurev.physiol.64.081501.155828 Dacic, 2007, Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis, Expert Rev Mol Diagn, 7, 77, 10.1586/14737159.7.1.77 2004 Field, 1999, Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer, Cancer Research, 59, 2690 Wang, 2006, Molecular diagnostic markers for lung cancer in sputum and plasma, Ann NY Acad Sci, 1075, 179, 10.1196/annals.1368.024 Pathak, 2006, Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool, Clin Chem, 52, 1833 Chan, 2007, Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers, Br J Cancer, 96, 681, 10.1038/sj.bjc.6603625 Gormally, 2007, Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance, Mutat Res, 635, 105, 10.1016/j.mrrev.2006.11.002 Picozzi, 2005, Screening of lung cancer with low dose spiral CT: results of a three year pilot study and design of the randomised controlled trial ‘Italung-CT”, Radiol Med, 109, 17 ITALUNG Study Research Group, 2009, Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT, Lung Cancer, 64, 34, 10.1016/j.lungcan.2008.07.003 Liloglou, 2000, Sensitivity and limitations of high thoughput fluorescent microsatellite analysis for the detection of allelic imbalance. Application in lung tumor, Int J Oncol, 16, 5 Coulet, 2000, Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis, Cancer Res, 60, 707 Andriani, 2004, Detecting lung cancer in plasma with the use of multiple genetic markers, Int J Cancer, 108, 91, 10.1002/ijc.11510 Levi, 1991, Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique, Cancer Res, 51, 3497 Guldberg, 1997, Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer, Hum Mutat, 9, 348, 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.0.CO;2-1 Cremonesi, 1999, Validation of double gradient denaturing gradient gel electrophoresis through multigenic retrospective analysis, Clin Chem, 45, 35, 10.1093/clinchem/45.1.35 Sozzi, 2003, Quantification of free circulating DNA as a diagnostic marker in lung cancer, J Clin Oncol, 21, 3902, 10.1200/JCO.2003.02.006 Schäfer, 1989, Constructing a cut-off point for a quantitative diagnostic test, Stat Med, 8, 1381, 10.1002/sim.4780081110 Sozzi, 2001, Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients, Cancer Res, 61, 4675 Kirk, 2000, Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia, J Natl Cancer Inst, 92, 148, 10.1093/jnci/92.2.148 Esteller, 1999, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients, Cancer Res, 59, 3853 Liloglou, 2000, Sensitivity and limitations of high throughput fluorescent microsatellite analysis for the detection of allelic imbalance. Application in lung tumor, Int J Oncol, 16, 5 Pan, 2005, Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer, Cancer Res, 65, 1664, 10.1158/0008-5472.CAN-04-3297 Wistuba, 1997, Molecular damage in the bronchial epithelium of current and former smokers, J Natl Cancer Inst, 89, 1366, 10.1093/jnci/89.18.1366 Zienolddiny, 2001, Loss of heterozygosity is related to p53 mutations and smoking in lung cancer, Br J Cancer, 84, 226, 10.1054/bjoc.2000.1528 Tseng, 2005, Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer, Int J Cancer, 117, 241, 10.1002/ijc.21178 Sozzi, 2005, Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays, Natl Cancer Inst, 97, 1848, 10.1093/jnci/dji432 Sozzi, 2009, Plasma DNA quantification in lung cancer CT screening: 5-years results of a prospective study, Am J Respir Crit Care Med, 179, 69, 10.1164/rccm.200807-1068OC Kersting, 2000, Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers, J Clin Oncol, 18, 3221, 10.1200/JCO.2000.18.18.3221 Baryshnikova, 2008, Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program, Clin Cancer Res, 14, 1913, 10.1158/1078-0432.CCR-07-1741 Shaipanich, 2006, Early detection and chemoprevention of lung cancer, Respirology, 11, 366, 10.1111/j.1440-1843.2006.00860.x Nelson, 1999, Implications and prognostic value of K-ras mutation for early-stage lung cancer in women, J Natl Cancer Inst, 91, 2032, 10.1093/jnci/91.23.2032 Silva, 1999, Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations, Cancer Res, 59, 3251 Medic, 2007, Molecular markers of circulating melanoma cells, Pigment Cell Res, 20, 80, 10.1111/j.1600-0749.2006.00356.x